Literature DB >> 24297679

Need for a biomarker to de-escalate antimicrobial empirical therapy.

José Garnacho-Montero1, Antonio Gutiérrez-Pizarraya2, Ana Escoresca-Ortega2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24297679     DOI： 10.1007/s00134-013-3177-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  2 in total

1.  Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies.

Authors:  Y X Liew; W Lee; Y Y Cai; J Teo; S S-L Tang; R W-Q Ong; C L-L Lim; P B Lingegowda; A L-H Kwa; M P Chlebicki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-08       Impact factor: 3.267

2.  Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes.

Authors:  Philipp Schuetz; Beat Mueller
Journal:  Intensive Care Med       Date:  2013-10-30       Impact factor: 17.440
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.